This targeting approach was used, among others, in the fibronectin gene, Ullrich congenital muscular dystrophy (UCMD), and growth hormone deficiency (GHD) type II diseases [72,73,74]. This evidence concerns the gene FN1 and Ullrich congenital muscular dystrophy.